By Rajnish Mago, MD (bio) THIS PAGE IS STILL UNDER CONSTRUCTION As of September 2019, the following long-acting injectable (LAI) antipsychotics have FDA-approval for the treatment of bipolar disorders: Risperidone long-acting injection: “as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of Bipolar I Disorder” Aripiprazole for extended-release injectable suspension:…